The MAGE‐A4, MAGE‐A1, MAGE‐A3, OY‐TES‐1, and MAGE‐C expressions were shared in 95% of ovarian cancer cases, while the expression levels of SP17, GAGE, NY‐ESO‐1, and XAGE‐1D were found to be closely associated with an increased risk of tumor progression. Here, SPA17 is linked to ovarian carcinoma.